← Back to graph
Prescription

upadacitinib atopic dermatitis

Selected indexed studies

  • Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. (Health Technol Assess, 2024) [PMID:38343072]
  • Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (JAMA Dermatol, 2021) [PMID:34347860]
  • Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. (Lancet, 2021) [PMID:34023008]

_Worker-drafted node — pending editorial review._

Connections

upadacitinib atopic dermatitis is a side effect of

Sources

Local graph